deoxycytidine and Kidney Neoplasms

deoxycytidine has been researched along with Kidney Neoplasms in 157 studies

Research

Studies (157)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (4.46)18.2507
2000's80 (50.96)29.6817
2010's65 (41.40)24.3611
2020's5 (3.18)2.80

Authors

AuthorsStudies
Cao, H; Liu, G; Shao, F; Yan, L; Zhang, H1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z1
Fukami, N; Fukaya, K; Ichino, M; Kusaka, M; Nukaya, T; Sasaki, H; Shiroki, R; Sumitomo, M; Takahara, K; Takenaka, M; Zennami, K1
Cao, T; Fan, D; Gao, X; Gao, Z; Guo, F; Luo, X; Xing, Q; Yang, F; Zhang, L; Zhang, S1
Barocas, DA; Bivalacqua, TJ; Black, PC; Cookson, MS; D'Andrea, D; Dall'Era, MA; Daneshmand, S; Dinney, CP; Holzbeierlein, JM; Kassouf, W; Lotan, Y; Matin, S; McGrath, JS; Morgan, TM; North, S; Petros, FG; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BW; Wright, JL; Zargar, H1
Gürses, E; Kemal, HS; Kültürsay, H; Özbay, B; Şimşek, E1
Farrow, JM; Gryzinski, GM; Kern, SQ; Sundaram, CP1
An, X; Deng, YF; Jiang, WQ; Li, LR; Shao, C; Shi, YX; Sun, P; Thomas, R; Xue, C; Yang, W1
Fujita, N; Hamano, I; Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Iwamura, H; Koie, T; Kusaka, A; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T1
Klang, E; Lawson, P; Michal Amitai, M; Yonat, H1
Bivalacqua, TJ; Gupta, M; Hahn, NM; Johnson, MH; Kates, M; Liao, RS; McConkey, D; Patel, HD; Pierorazio, PM; Schwen, ZR1
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H1
Balasubramanian, A; Davis, JW; Dinney, CP; Kamat, AM; Karam, JA; Matin, SF; Metcalfe, MJ; Navai, N; Papadopoulos, J; Wagenheim, G; Wood, CG; Xiao, L1
Kumar, S; Narain, TA; Sharma, G; Tyagi, S1
Bae, WK; Lee, HJ; Lee, JL; Park, I; Yoon, S1
Apolo, AB; Bajorin, DF; Halabi, S; Iasonos, A; Milowsky, MI; Ostrovnaya, I; Philips, GK; Riches, J; Rosenberg, JE; Small, EJ1
Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A1
Conter, HJ; Lim, ZD; Millikan, RE; Ng, CS; Tannir, NM1
Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nagata, C; Nagumo, Y; Nishiyama, H; Oikawa, T; Suetomi, T; Uchida, M1
Albiges, L; Allory, Y; Bigot, F; Escudier, B; Gachet, J; Massard, C; Méjean, A; Oudard, S; Pécuchet, N; Teghom, C1
Enomoto, H; Imai, H; Kise, H; Kobayashi, M; Nomura, Y; Wakita, T; Yamamoto, I1
Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C1
Brunetti, O; Dei Tos, AP; Gesualdo, L; Silvestris, F; Stucci, S; Tucci, M; Vallarelli, S1
Guo, X; Jiao, S; Jing, F; Li, J; Linghu, R; Liu, M; Yang, J; Zhu, Y1
Bearz, A; Bozzetti, R; Buti, S; Caminiti, C; Camisaschi, C; Castelli, C; Donini, M; Lazzarelli, S; Lo Re, G; Mattioli, R; Passalacqua, R; Rivoltini, L; Simonelli, C1
Chen, K; Gumireddy, K; Huang, Q; Li, A; Li, H; Tang, K; Wang, J; Xiao, H; Xiao, W; Xu, H; Yao, W; Ye, Z; Yu, G1
Aydin, S; Gizzi, M; Machiels, JP1
Papadopoulos, EI; Scorilas, A; Yousef, GM1
Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K1
Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F1
Inoue, A; Kamada, S; Kitoh, H; Miyazaki, K; Nagata, M; Nozumi, K; Okatoh, A1
Apolo, AB; Bajorin, DF; Furberg, HF; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Tully, CM; Zabor, EC1
Culine, S; Kránitz, N; Kullmann, T; Pintér, T; Szepesvári, Z1
Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME1
Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S1
Cho, MH; Chung, J; Joung, JY; Kim, SH; Lee, KH; Park, WS; Seo, HK1
Alazraki, A; Carden, MA; Meany, H; Rapkin, LB; Smith, S; Yin, H1
Atkins, MB; Choueiri, TK; Jay, R; McDermott, DF; McKay, RR; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L1
Jonasch, E; Mathew, P; Ng, CS; Pagliaro, L; Siefker-Radtke, A; Tannir, NM; Thall, PF; Wang, X; Wood, C; Wooten, L1
Hampton, T1
Alhasan, S; Baranowski, K; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, U1
Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J1
Harshman, LC; Li, M; Srinivas, S1
Haseke, N; Ihrler, S; Karl, A; Schöppler, G; Siebels, M; Stadler, T; Staehler, M; Stief, CG2
Clark, JI; Crawford, DE; Gandour-Edwards, R; Hussey, M; Lange, MK; Lara, PN; Mack, PC; Van Veldhuizen, PJ1
Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG1
Beijnen, JH; Huitema, AD; Jansen, RS; Koolen, SL; Schellens, JH; Smit, WM; van Voorthuizen, T1
Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L1
Kellokumpu-Lehtinen, PL; Koskinen, S; Sunela, KL1
Bartel, P; Ecke, TD; Gerullis, H; Koch, S; Ruttloff, J1
Andreu, J; Carles, J; Serrano, C; Suárez, C1
Choi, DW; Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, SH; Park, YS1
Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K1
Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA1
Grossgoupil, M; Ravaud, A1
Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM1
Iwata, H; Miyazawa, M; Sato, H; Takano, Y; Ueno, K; Virgona, N; Yano, T; Yano, Y1
Abbou, CC; De La Taille, A; Diao, B; Esquivel, S; Paule, B; Salomon, L1
Buti, S; Caminiti, C; Chiesa, MD; Donini, M; Lazzarelli, S; Lheshi, A; Mattioli, R; Mazza, G; Passalacqua, R; Re, GL; Simon, S; Simonelli, C1
Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG1
Dutcher, JP; Nanus, D1
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ1
Fukuhara, H; Inoue, K; Kamada, M; Matumoto, M; Nishikawa, H; Shuin, T; Tamura, K; Yamasaki, I1
Friedman, GK; Hilliard, LM; Kelly, DR; Vaid, YN; Walsh, A1
Jonasch, E; Lim, ZD; Ng, C; Richey, SL; Tannir, NM1
Dutcher, J; Haas, NB; Heath, E; Lin, X; Liu, G; Manola, J; McDermott, D; Nanus, D; Pins, M; Wilding, G1
Cho, DC; McDermott, DF; Mier, JW; Pandya, SS1
Atkinson, BJ; Byfield, SD; Feng, C; Jonasch, E; Lal, LS; Miller, LA; Pagliaro, LC; Tannir, NM1
Paglino, C; Porta, C1
Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I1
Hernández-Fernández, C; Herranz-Amo, F; Husillos, A; Lledó, E; Molina-Escudero, R; Subirá, D1
Tanji, N; Yokoyama, M1
Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C1
Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J1
de Clermont, H; Dilhuydy, MS; Gross-Goupil, M; Ravaud, A; Roubaud, G; Wallerand, H1
Rexer, H1
Chiba, S; Habuchi, T; Inoue, T; Kanda, S; Kumazawa, T; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H1
Chikaraishi, T; Kimura, K; Kudo, H; Miyano, S; Nakazawa, R; Sasaki, H1
Engehausen, DG; Giedl, J; Goebell, PJ; Hartmann, A; Keck, B; Kunath, F; Wullich, B1
Araujo, JC; Jonasch, E; Lim, ZD; Lin, E; Ng, CS; Pagliaro, LC; Richey, SL; Sharma, P; Tamboli, P; Tannir, NM1
Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R1
Ryan, CW; Stadler, WM; Vogelzang, NJ1
Cini, G; Di Cello, V; Dominici, A; Doni, L; Fulignati, C; Gemelli, MT; Maleci, M; Mottola, A; Neri, B; Ponchietti, R; Raugei, A; Turrini, M; Valsuani, G1
Budd, GT; Bukowski, RM; Elson, P; Olencki, T; Peereboom, D; Perez-Zincer, F1
Antonuzzo, A; Chioni, A; Conte, P; Francesca, F; Galli, L; Iannopollo, M; Orlandini, C; Ricci, S; Selli, C; Vocaturo, V1
Ansari, R; Desai, AA; Krauss, S; Rini, BI; Stadler, WM; Vogelzang, NJ1
Fuxius, S; Mansouri, K; Mross, K; Unger, C1
Culine, S1
Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R1
Amato, RJ1
Sternberg, CN; Vogelzang, NJ1
Johansson, R; Kataja, V; Pulkkanen, K1
Debré, B; Oudard, S; Peyromaure, M; Scotté, F; Thiounn, N; Vieillefond, A1
George, C; Huo, D; Karrison, T; Ryan, CW; Stadler, WM; Vogelzang, NJ; Yang, X; Zimmerman, TM1
Bartsch, R; Hussian, D; Kramer, G; Lintner, C; Locker, GJ; Mader, R; Marberger, M; Pluschnig, U; Rauchenwald, M; Steger, GG; Wenzel, C; Zielinski, CC1
Danova, M; Imarisio, I; Natalizi, A; Porta, C; Riccardi, A; Sartore-Bianchi, A; Zimatore, M1
Stadler, WM1
Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N1
Aksu, G; Fayda, M; Kapran, Y; Sakar, B1
Dutcher, JP; Garino, A; Larkin, M; Milowsky, MI; Nanus, DM1
Merimsky, O1
A'hern, R; Eisen, T; Gore, M; Hackett, S; James, M; Moss, C; Pyle, L; Waters, JS1
Berg, W; Olgac, S; Reuter, V; Scher, H; Slovin, SF1
Arceci, RJ; Loeb, DM; Mack, AK; Small, D; Spevak, M; Strouse, JJ1
Rini, BI; Small, EJ; Weinberg, V1
Comella, P; Crucitta, E; De Lena, M; Gebbia, V; Lorusso, V; Mancarella, S; Mangiameli, A; Manzione, L; Muci, D; Palmeri, S; Pezzella, G; Rosati, G; Silvestris, N; Sobrero, A1
Fukui, I; Hanada, E; Ishikawa, Y; Nakagawa, K; Okubo, Y; Satoh, Y; Tadokoro, M; Tsukamoto, T; Yonese, J1
Bonsignori, M; Burattini, L; Marcucci, F; Massacesi, C1
Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T1
Guardino, AE; Srinivas, S1
Habuchi, T; Hatakeyama, S; Horikawa, Y; Inoue, T; Matsuura, S; Ohyama, C; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N1
Pfister, C1
Bannowsky, A; Hamann, M; Hautmann, S; Jünemann, KP; Naumann, M; Wefer, B1
Balassy, C; Fakhrai, N; Haitel, A; Schmidinger, M; Zielinski, CC1
Amato, RJ; Rawat, A1
Bell, MD1
Aragoncillo, P; Casado Herraez, A; Díaz-Rubio García, E; Gómez Díaz, R; Moreno Antón, F; Puente Vázquez, J1
Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Dal Bianco, M; De Zorzi, L; Pastorelli, D; Salmaso, F; Zovato, S; Zustovich, F1
Cartei, G; Pavei, P; Zustovich, F1
Atzpodien, J; Fornara, P; Gertenbach, U; Hauser, S; Heinzer, H; Heynemann, H; Huland, E; Kirchner, H; Leiber, C; Metzner, B; Müller, SC; Raschke, R; Rebmann, U; Reitz, M; Roigas, J; Salm, S; Schwindl, B; Siebels, M; Siemer, S; Soder, M1
Barrier, R; Davila, E; Ernstoff, MS; Halabi, S; Picus, J; Rini, B; Small, EJ; Stadler, WM1
Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E1
Arakelyan, N; Banu, A; Banu, E; Culine, S; Duclos, B; Escudier, B; Fournier, L; Medioni, J; Oudard, S; Priou, F; Rolland, F; Vieillefond, A1
Ito, N; Kamoto, T; Ogawa, O; Shang, D1
Huang, WT; Kuo, CY; Li, SH1
Bukowski, R; Desai, AA; Kardinal, CG; Lewis, N; Makalinao, A; Murray, P; Poiesz, B; Quinn, DI; Stadler, WM; Torti, FM1
Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A1
Kubota, Y; Makiyama, K; Nakaigawa, N; Oshiro, H; Sugiura, S; Yao, M1
Amato, RJ; Khan, M1
Fléchon, A1
Alberici, F; Bongiovanni, C; Brighenti, M; Buti, S; Buzio, C; Chiesa, MD; Passalacqua, R1
Faerber, GJ; Weizer, AZ; Wolf, JS1
Chen, HH; Cheng, YC; Lim, KH; Lin, CJ; Wu, CJ1
Chung, J; Han, KS; Jeong, IG; Joung, JY; Kim, TS; Lee, KH; Seo, HK1
Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T1
Ackermann, H; Gruber, T; Nabil, M; Vogl, TJ; Yakoub, D; Zangos, S1
Fujiwara, Y; Gemba, K; Hotta, K; Kiura, K; Omori, M; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S1
Amato, RJ; Mohammad, T1
Eisenhauer, EA; Mertens, WC; Moore, M; Muldal, A; Stewart, D; Venner, P; Wong, D1
Blatter, J; De Mulder, PH; Jakse, G; Osieka, R; Weissbach, L1
Ernst, DS; Huan, S; Moore, MJ; Murray, N; Tannock, IF1
Blatter, J; Hayn, HK; Jakse, G; Rohde, D1
Blatter, J; Goertz, M; Jakse, G; Rohde, D1
Reeves, W; Tippin, DB; Vogelzang, NJ1
Bennett, K; Huan, S; Moore, MJ; Murray, N; Seymour, L; Tannock, IF; Walsh, W; Winquist, EW1
Akaza, H; Hattori, K1
Dumas, MC; Rini, BI; Stadler, WM; Taber, DA; Vogelzang, NJ; Wade, JL1
Atzpodien, J; Buer, J; Franzke, A; Hoffmann, R; Kirchner, H; Oevermann, K; Patzelt, T; Schrader, A1
Matsuzaki, A; Morita, T; Tokue, A1
Casali, A; Casali, M; Ferrone, C; Galante, E; Giuntini, T; Marcellini, M1
Twelves, C1
Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ1
Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC1
Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D1
Milowsky, MI; Nanus, DM; Papanicolaou, N; Rosmarin, A; Tickoo, SK1
Vogelzang, NJ1

Reviews

20 review(s) available for deoxycytidine and Kidney Neoplasms

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Nephron-sparing management of upper tract urothelial carcinoma.
    Investigative and clinical urology, 2021, Volume: 62, Issue:4

    Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Mitomycin; Neoplasm Staging; Nephrectomy; Nephrons; Organ Sparing Treatments; Ureteral Neoplasms; Ureteroscopy

2021
Breast carcinoma with choriocarcinomatous features: a case report and review of the literature.
    World journal of surgical oncology, 2014, Jul-30, Volume: 12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Choriocarcinoma; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Cyclobutanes; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Giant Cells; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Organoplatinum Compounds; Prognosis; Retrospective Studies; Taxoids

2014
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
    World journal of urology, 2017, Volume: 35, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms

2017
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
    World journal of surgical oncology, 2016, Oct-20, Volume: 14, Issue:1

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chondrosarcoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures

2016
Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.
    The oncologist, 2009, Volume: 14, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Nephrectomy; Palliative Care; Renal Dialysis; Urologic Neoplasms

2009
[Renal medullary carcinoma: remission with gemcitabine-cisplatin and review of therapeutic perspectives].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2010, Volume: 20, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Remission Induction

2010
[Granulocyte-colony stimulating factor producing squamous cell carcinoma of the renal pelvis: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2010, Volume: 56, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Kidney Pelvis; Organoplatinum Compounds

2010
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
    Clinical and experimental nephrology, 2011, Volume: 15, Issue:3

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2011
[Gemcitabine and urogenital tumors].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Germinoma; Hematologic Diseases; Humans; Kidney Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Patient Selection; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms; Vinblastine

2002
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
    International journal of clinical oncology, 2003, Volume: 8, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome

2003
Thalidomide therapy for renal cell carcinoma.
    Critical reviews in oncology/hematology, 2003, Jun-27, Volume: 46 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Thalidomide

2003
Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.
    Critical reviews in oncology/hematology, 2003, Jun-27, Volume: 46 Suppl

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Kidney Neoplasms; Paclitaxel; Pemetrexed; Urogenital Neoplasms; Urothelium

2003
Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
    Pediatric blood & cancer, 2005, Volume: 44, Issue:4

    Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel; Treatment Outcome

2005
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan

2006
[Gemcitabine and pemetrexed in genito-urinary tumors treatment].
    Bulletin du cancer, 2007, Volume: 94 Spec No Actualites

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Kidney Neoplasms; Methotrexate; Pemetrexed; Urologic Neoplasms; Vinblastine

2007
[New combination chemotherapy in urological cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine

2000
Vision of the future: capecitabine.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Ovarian Neoplasms; Pancreatic Neoplasms

2001
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
    Cancer, 2002, Jan-01, Volume: 94, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids

2002
Future directions for gemcitabine in the treatment of genitourinary cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Forecasting; Gemcitabine; Humans; Kidney Neoplasms; Male; Morbidity; Prostatic Neoplasms; Survival Analysis; Testicular Neoplasms; Treatment Outcome; United States; Urinary Bladder Neoplasms; Urogenital Neoplasms

2002

Trials

53 trial(s) available for deoxycytidine and Kidney Neoplasms

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecologic oncology, 2018, Volume: 148, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome

2018
A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
    Investigational new drugs, 2019, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome

2019
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
    Targeted oncology, 2015, Volume: 10, Issue:2

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cell Separation; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Recombinant Proteins; T-Lymphocytes, Regulatory; Time Factors; Treatment Outcome

2015
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    The Journal of urology, 2008, Volume: 180, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome

2008
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
    Urology, 2008, Volume: 72, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Middle Aged; Taxoids

2008
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nephrectomy; Survival Rate; Thalidomide; Treatment Outcome

2008
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    American journal of clinical oncology, 2009, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Prognosis; PTEN Phosphohydrolase; Thymidylate Synthase; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein

2009
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
    German medical science : GMS e-journal, 2009, Jun-10, Volume: 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Germany; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prodrugs; Survival Rate; Thalidomide; Treatment Outcome

2009
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Treatment Outcome

2010
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis

2010
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
    American journal of clinical oncology, 2011, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis

2011
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2010, Volume: 33, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Intention to Treat Analysis; Interferon-alpha; Interleukin-2; Italy; Kidney Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Metastasis; Survival Analysis

2010
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
    European journal of medical research, 2010, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib

2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2011
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate

2012
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:3

    Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate

2012
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Capecitabine; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Etoricoxib; Female; Fluorouracil; Follow-Up Studies; Humans; Hypoglycemic Agents; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pioglitazone; Prognosis; Prospective Studies; Pyridines; Sulfones; Survival Rate; Thiazolidinediones

2012
[First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced o
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms; Vinblastine

2011
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
    American journal of clinical oncology, 2013, Volume: 36, Issue:5

    Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Young Adult

2013
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Cancer, 2002, May-15, Volume: 94, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome

2002
Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
    The Journal of urology, 2002, Volume: 168, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Injections, Intramuscular; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged

2002
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
    Investigational new drugs, 2002, Volume: 20, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Recombinant Proteins

2002
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
    Cancer, 2002, Oct-01, Volume: 95, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms

2002
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
    Cancer, 2002, Oct-15, Volume: 95, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Heart Arrest; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Thalidomide; Thromboembolism

2002
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome

2002
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
    The Journal of urology, 2003, Volume: 170, Issue:4 Pt 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Prognosis; Survival Rate

2003
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
    Anti-cancer drugs, 2003, Volume: 14, Issue:10

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunologic Factors; Immunotherapy; Interferon-gamma; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins

2003
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
    Cancer, 2004, May-15, Volume: 100, Issue:10

    Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Sarcoma; Survival Rate; Therapeutics; Treatment Outcome

2004
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    British journal of cancer, 2004, Nov-15, Volume: 91, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome

2004
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
    Cancer, 2005, Feb-01, Volume: 103, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Hematologic Diseases; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Treatment Outcome

2005
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
    Oncology reports, 2005, Volume: 13, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Time Factors; Urinary Bladder Neoplasms; Urothelium

2005
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
    American journal of clinical oncology, 2005, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium

2005
A nonplatinum combination in metastatic transitional cell carcinoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms

2005
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
    Investigational new drugs, 2006, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome

2006
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan

2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    British journal of cancer, 2006, Aug-21, Volume: 95, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis

2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
    Cancer, 2006, Sep-15, Volume: 107, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome

2006
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
    Investigational new drugs, 2007, Volume: 25, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance

2007
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
    The Journal of urology, 2007, Volume: 177, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome

2007
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis

2008
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
    Anti-cancer drugs, 2007, Volume: 18, Issue:7

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prodrugs; Remission Induction; Survival Rate; Treatment Failure

2007
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Recombinant Proteins; Thalidomide

2008
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Texas; Thalidomide; Treatment Outcome

2008
Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local

1993
Gemcitabine: a phase II study in patients with advanced renal cancer.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged

1996
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:12

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms

1997
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Thrombocytopenia; Ureteral Neoplasms; Urinary Bladder Neoplasms

1999
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Treatment Outcome

2000
Capecitabine in the treatment of metastatic renal cell carcinoma.
    British journal of cancer, 2000, Volume: 83, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome

2000
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Cancer, 2001, Sep-15, Volume: 92, Issue:6

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome

2001
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 39, Issue:1

    Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Nausea; Prodrugs; Stomatitis; Survival Analysis; Treatment Failure; Treatment Outcome; Vomiting

2002
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, Liquid; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Mass Spectrometry; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Peripheral Nervous System Diseases

2001

Other Studies

86 other study(ies) available for deoxycytidine and Kidney Neoplasms

ArticleYear
Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation.
    Biochemical and biophysical research communications, 2019, 10-29, Volume: 519, Issue:1

    Topics: Animals; Autophagy; Base Sequence; Cell Line, Tumor; Cyclin B1; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Circular

2019
Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
    BJU international, 2021, Volume: 127, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Sex Factors; Survival Rate; Ureteral Neoplasms; Vinblastine

2021
Right supernumerary kidney with urothelial carcinoma: A case report.
    Medicine, 2020, Sep-18, Volume: 99, Issue:38

    Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Nephroureterectomy; Ureter

2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    BJU international, 2021, Volume: 127, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comparative Effectiveness Research; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Vinblastine

2021
Takotsubo syndrome early after treatment due to non cardiotoxic chemotherapy agents.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2021, Volume: 49, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma; Cardiotoxicity; Deoxycytidine; Echocardiography; Electrocardiography; Female; Gemcitabine; Humans; Kidney Neoplasms; Myocardial Infarction; Takotsubo Cardiomyopathy; Vinorelbine

2021
The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
    Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Retrospective Studies; Risk Factors; Ureteral Neoplasms

2017
Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
    European urology focus, 2018, Volume: 4, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Prognosis; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urologic Surgical Procedures

2018
Metastatic Collecting (Bellini) Duct Carcinoma Presented in a Young Patient: A Case Report and Review of the Literature.
    The Israel Medical Association journal : IMAJ, 2017, Volume: 19, Issue:12

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Ductal; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Iliac Vein; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiography, Abdominal; Spleen; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis

2017
Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    The Journal of urology, 2018, Volume: 200, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephroureterectomy; Retrospective Studies; Ureter; Ureteral Neoplasms

2018
Salvage topical therapy for upper tract urothelial carcinoma.
    World journal of urology, 2018, Volume: 36, Issue:12

    Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Mitomycin; Nephrostomy, Percutaneous; Retrospective Studies; Salvage Therapy; Treatment Outcome; Ureteral Neoplasms; Urinary Catheterization

2018
Bilateral leiomyosarcoma of kidneys with pericardial metastases: a double whammy.
    BMJ case reports, 2019, Mar-20, Volume: 12, Issue:3

    Topics: Administration, Intravenous; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Kidney Neoplasms; Leiomyosarcoma; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography

2019
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
    Journal of the National Cancer Institute, 2013, Apr-03, Volume: 105, Issue:7

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kidney Neoplasms; Male; Middle Aged; Nomograms; Paclitaxel; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Urothelium

2013
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14

    Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine

2013
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:3

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Remission Induction

2013
[Long-term survival with gemcitabine and docetaxel for renal leiomyosarcoma : a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kidney Neoplasms; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Pancreatic Neoplasms; Taxoids

2013
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Maintenance Chemotherapy; Middle Aged; Treatment Outcome

2013
[Granulocyte-colony stimulating factor-producing urothelial carcinoma of right renal pelvis : a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Kidney Pelvis; Urothelium

2013
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
    The oncologist, 2014, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium

2014
Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-10, Volume: 33, Issue:14

    Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Diagnosis, Differential; Drug Administration Schedule; Fluorodeoxyglucose F18; Gemcitabine; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Neoplasms; Lymph Node Excision; Male; Nephrectomy; Obesity; Paraneoplastic Syndromes; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging

2015
Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:12

    Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MicroRNAs; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pseudogenes; PTEN Phosphohydrolase; RNA Interference; RNA, Messenger; Tumor Burden

2014
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
    Urologia internationalis, 2015, Volume: 94, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome

2015
Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:5

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression; Humans; Kidney Neoplasms; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Urinary Bladder Neoplasms

2015
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
    BMC cancer, 2015, May-22, Volume: 15

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2015
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting

2015
[A CASE OF HEPATIC METASTASECTOMY FOR RENAL PELVIS CARCINOMA].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2015, Volume: 106, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Kidney Neoplasms; Laparoscopy; Liver Neoplasms; Metastasectomy; Nephrectomy; Pelvic Neoplasms; Recurrence

2015
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
    Cancer, 2016, Mar-01, Volume: 122, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Kidney Neoplasms; Kidney Pelvis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Retrospective Studies; Stroke; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Venous Thromboembolism

2016
[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
    Orvosi hetilap, 2016, Mar-13, Volume: 157, Issue:11

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Anuria; Carcinoma, Renal Cell; Cisplatin; Creatinine; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematuria; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Palliative Care; Renal Dialysis; Tomography, X-Ray Computed; Treatment Outcome

2016
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    British journal of cancer, 2016, 08-09, Volume: 115, Issue:4

    Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays

2016
Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
    Pediatric blood & cancer, 2017, Volume: 64, Issue:7

    Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Medullary; Child; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel

2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015
    Urologic oncology, 2017, Volume: 35, Issue:3

    Topics: Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Sunitinib

2017
Clinical trials probe new therapies for some difficult-to-treat cancers.
    JAMA, 2008, Jul-23, Volume: 300, Issue:4

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Everolimus; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Pancreatic Neoplasms; Sirolimus

2008
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
    International journal of oncology, 2008, Volume: 33, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays

2008
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
    European journal of medical research, 2008, Nov-24, Volume: 13, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib

2008
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome

2009
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
    JOP : Journal of the pancreas, 2009, Sep-04, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome

2009
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2009, Volume: 61, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms

2009
Acute aortic dissection during sorafenib-containing therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Survival Rate; Treatment Outcome

2010
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2010, Volume: 56, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms

2010
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling.
    Biochemical pharmacology, 2010, Aug-15, Volume: 80, Issue:4

    Topics: Azacitidine; Carcinoma, Renal Cell; Cell Proliferation; Connexins; Decitabine; Deoxycytidine; Down-Regulation; Enzyme Activation; Gap Junction beta-1 Protein; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Kidney Neoplasms; Signal Transduction; Transcriptional Activation; Up-Regulation; Vinblastine

2010
Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome

2011
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
    Pediatric blood & cancer, 2010, Dec-01, Volume: 55, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Renal Cell; Child; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel; Sickle Cell Trait; Treatment Outcome

2010
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Remission Induction; Time Factors; Tomography, X-Ray Computed; Treatment Failure

2011
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
    BJU international, 2011, Volume: 108, Issue:8 Pt 2

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib

2011
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
    BJU international, 2011, Volume: 107, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Epidemiologic Methods; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome

2011
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
    BJU international, 2011, Volume: 107, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Treatment Outcome

2011
[Collecting duct renal cell carcinoma].
    Actas urologicas espanolas, 2011, Volume: 35, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Incidental Findings; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Staging; Nephrectomy; Prognosis; Retrospective Studies; Sirolimus; Survival Analysis

2011
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
    Current opinion in oncology, 2011, Volume: 23 Suppl

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A

2011
Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome

2011
[Granulocyte colony stimulating factor-producing spindle cell renal cell carcinoma successfully treated by chemotherapy consisting of gemcitabine and doxorubicin].
    Hinyokika kiyo. Acta urologica Japonica, 2011, Volume: 57, Issue:7

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Middle Aged

2011
Synchronous bilateral urothelial cancer in a kidney recipient.
    International journal of urology : official journal of the Japanese Urological Association, 2011, Volume: 18, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Neoplasms, Multiple Primary; Ureteral Neoplasms; Urothelium

2011
Clinical course of plasmacytoid urothelial carcinoma of the upper urinary tract: a case report.
    Urologia internationalis, 2012, Volume: 89, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lymph Node Excision; Lymphatic Metastasis; Male; Nephrectomy; Treatment Failure; Urothelium

2012
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
    Onkologie, 2012, Volume: 35, Issue:12

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2012
Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:3

    Topics: Biopsy, Needle; Capillary Leak Syndrome; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Pulmonary Edema; Risk Assessment; Severity of Illness Index

2003
Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases.
    The Journal of urology, 2003, Volume: 170, Issue:4 Pt 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Neoplasm Staging

2003
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
    Der Urologe. Ausg. A, 2004, Volume: 43 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Neoplasm Metastasis; Survival Rate

2004
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2004, Volume: 50, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine

2004
Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis.
    International journal of gastrointestinal cancer, 2003, Volume: 34, Issue:2-3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Male; Neoplastic Cells, Circulating; Nephrectomy

2003
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
    Cancer, 2004, Oct-01, Volume: 101, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Sarcoma

2004
Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation.
    International journal of molecular medicine, 2004, Volume: 14, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diabetic Nephropathies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Kidney Transplantation; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Sirolimus; Tomography, X-Ray Computed; Treatment Outcome

2004
Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor.
    Cancer investigation, 2004, Volume: 22, Issue:5

    Topics: Adrenal Gland Neoplasms; Adult; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Heart Neoplasms; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Tomography, X-Ray Computed

2004
Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.
    International journal of urology : official journal of the Japanese Urological Association, 2005, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Middle Aged; Salvage Therapy

2005
Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2005, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Thrombocytopenia

2005
[Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2005, Volume: 51, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged

2005
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Muller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S, Moritz T. Ann. Hematol. 2005 Feb; 84(2):110-4.
    Annals of hematology, 2005, Volume: 84, Issue:9

    Topics: Adult; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Neoplasms; Male; Multiple Organ Failure

2005
["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
    Der Urologe. Ausg. A, 2005, Volume: 44, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Tomography, X-Ray Computed

2005
Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
    Wiener klinische Wochenschrift, 2005, Volume: 117, Issue:1-2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Palliative Care; Thalidomide; Treatment Failure; Treatment Outcome

2005
Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel

2006
Cardiac metastasis from uterine leiomyosarcoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Diagnostic Errors; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Ifosfamide; Kidney Neoplasms; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Taxoids; Temozolomide; Thoracic Surgery, Video-Assisted; Uterine Neoplasms

2006
Erysipeloid skin toxicity induced by gemcitabine.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2006, Volume: 20, Issue:6

    Topics: Aged; Ankle; Antimetabolites, Antineoplastic; Deoxycytidine; Erysipeloid; Gemcitabine; Humans; Kidney Neoplasms; Leg; Male; Skin

2006
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
    Urology, 2007, Volume: 69, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Caspases; Deoxycytidine; Drug Synergism; Flow Cytometry; Fluorouracil; History, Ancient; Humans; Kidney Neoplasms; Paclitaxel; Sensitivity and Specificity; Tumor Cells, Cultured; Vinblastine

2007
Metastatic urothelial carcinoma of upper urinary tract.
    American journal of hematology, 2007, Volume: 82, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Hematologic Diseases; Humans; Hypercalcemia; Kidney Neoplasms; Male; Middle Aged; Ureteral Neoplasms

2007
Collecting duct carcinoma producing granulocyte-colony-stimulating factor (G-CSF).
    International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:6

    Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Nephrectomy; Organoplatinum Compounds; Radiography

2007
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2007, Volume: 30, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies

2007
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
    Urology, 2007, Volume: 70, Issue:3

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy

2007
Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
    Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Kidney Neoplasms; Tumor Lysis Syndrome

2007
Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.
    British journal of cancer, 2008, Jan-15, Volume: 98, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome; Vinblastine

2008
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:3

    Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal Outcome; Floxuridine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Ureteral Neoplasms; Urinary Bladder Neoplasms

2008
Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results.
    European radiology, 2008, Volume: 18, Issue:7

    Topics: Adult; Aged; Carcinoma, Renal Cell; Chemoembolization, Therapeutic; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Iodized Oil; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Prospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2008
Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
    Anti-cancer drugs, 2008, Volume: 19, Issue:4

    Topics: Antimetabolites, Antineoplastic; Buttocks; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Tomography, X-Ray Computed

2008
The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines.
    International journal of oncology, 1998, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interferons; Kidney Neoplasms; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Vinblastine

1998
The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma.
    International journal of oncology, 1998, Volume: 12, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Interferons; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Remission Induction; Survival Analysis; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured; Vinblastine

1998
Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
    The Journal of urology, 1999, Volume: 162, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arachnoid; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Meningeal Neoplasms; Middle Aged

1999
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    International journal of cancer, 2001, May-01, Volume: 92, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxycytidine; Disease Models, Animal; DNA, Complementary; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study.
    Journal of experimental & clinical cancer research : CR, 2001, Volume: 20, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged

2001